immatics biotechnologies GmbH Cash Flow-to-Debt Ratio
immatics biotechnologies GmbH cash flow-to-debt ratio. immatics biotechnologies GmbH (IMTXW) has a Cash Flow-to-Debt Ratio of -0.33x as of March 2025, meaning its operating cash flow of $-34.21 Million could theoretically repay 0% of its total liabilities ($105.09 Million) in one year. Check IMTXW cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of immatics biotechnologies GmbH (2018–2024)
Cash flow-to-debt ratio of immatics biotechnologies GmbH from 2018 to 2024. Historical debt coverage capacity for immatics biotechnologies GmbH across 7 annual periods. Check cash flow reinvestment rate of immatics biotechnologies GmbH to assess the company's total reinvestment commitment from operating cash flow.
immatics biotechnologies GmbH Cash Flow-to-Debt Ratio by Year (2018–2024)
immatics biotechnologies GmbH cash flow-to-debt ratio by year from 2018 to 2024. Year-by-year debt coverage analysis for immatics biotechnologies GmbH. For the full cash flow conversion analysis, see IMTXW operating cash flow.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.30x | $-158.03 Million | $121.30 Million | ▼ -2136.1% |
| 2023 | 0.06x | $18.23 Million | $284.88 Million | ▼ -87.6% |
| 2022 | 0.51x | $100.13 Million | $194.66 Million | ▲ +194.7% |
| 2021 | -0.54x | $-81.78 Million | $150.58 Million | ▲ +4.6% |
| 2020 | -0.57x | $-85.61 Million | $150.39 Million | ▼ -240.5% |
| 2019 | 0.41x | $70.97 Million | $175.11 Million | ▲ +38.1% |
| 2018 | 0.29x | $20.68 Million | $70.49 Million | — |